274 related articles for article (PubMed ID: 15373046)
1. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
Goebel FD
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
[No Abstract] [Full Text] [Related]
2. [Strategies for combating resistances in HIV therapy--an exemplifying case].
Stoehr A
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
[No Abstract] [Full Text] [Related]
3. [Initial retroviral drug with new mechanism of action. Peptide T-20 enriches therapeutic arsenal].
MMW Fortschr Med; 2003 Apr; 145 Spec No 1():55-7. PubMed ID: 15011591
[No Abstract] [Full Text] [Related]
4. [HIV-1 fusion inhibitor improves treatment in HIV-1-resistant patients].
Blasko M
Dtsch Med Wochenschr; 2003 May; 128(19):1032. PubMed ID: 12774800
[No Abstract] [Full Text] [Related]
5. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
[TBL] [Abstract][Full Text] [Related]
6. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
8. [Fusion inhibitor enfuvirtidE. Continuous virologic and immunologic response].
Schäfer B
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():31. PubMed ID: 16385869
[No Abstract] [Full Text] [Related]
9. Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort.
Talbot A; Machouf N; Thomas R; Marcotte S; Therrien R; Lessard B; Dufresne S; Lalonde R
J Acquir Immune Defic Syndr; 2009 Jul; 51(3):362-4. PubMed ID: 19553775
[No Abstract] [Full Text] [Related]
10. Fuzeon data review.
GMHC Treat Issues; 2003 Mar; 17(3):6. PubMed ID: 12728857
[No Abstract] [Full Text] [Related]
11. Clinical trials for enfuvirtide (Fuzeon, T-20).
Crabb C
AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
[No Abstract] [Full Text] [Related]
12. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
Cervia JS; Smith MA
Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
[TBL] [Abstract][Full Text] [Related]
13. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
Streinu-Cercel A; de Gorgolas M; Müller M; Portilla J; Rugina S; Böcher W; Staszewski S; Pulik P; Rowell L; Salgo M; Stoll M
HIV Clin Trials; 2008; 9(6):375-86. PubMed ID: 19203903
[TBL] [Abstract][Full Text] [Related]
14. Use of darunavir and enfuvirtide in a pregnant woman.
Sued O; Lattner J; Gun A; Patterson P; Abusamra L; Cesar C; Fink V; Krolewiecki A; Cahn P
Int J STD AIDS; 2008 Dec; 19(12):866-7. PubMed ID: 19050223
[TBL] [Abstract][Full Text] [Related]
15. Fusion inhibition--a major but costly step forward in the treatment of HIV-1.
Tashima KT; Carpenter CC
N Engl J Med; 2003 May; 348(22):2249-50. PubMed ID: 12773653
[No Abstract] [Full Text] [Related]
16. Fusion inhibitors: T-20 and T-1249.
TreatmentUpdate; 2001; 12(12):2-3. PubMed ID: 11570088
[No Abstract] [Full Text] [Related]
17. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
Reynes J; Arastéh K; Clotet B; Cohen C; Cooper DA; Delfraissy JF; Eron JJ; Henry K; Katlama C; Kuritzkes DR; Lalezari JP; Lange J; Lazzarin A; Montaner JS; Nelson M; O' Hearn M; Stellbrink HJ; Trottier B; Walmsley SL; Buss NE; Demasi R; Chung J; Donatacci L; Guimaraes D; Rowell L; Valentine A; Wilkinson M; Salgo MP
AIDS Patient Care STDS; 2007 Aug; 21(8):533-43. PubMed ID: 17711378
[TBL] [Abstract][Full Text] [Related]
18. [Combined treatment with fusion inhibitor. HIV-1 viruses under control longer].
MMW Fortschr Med; 2004 Apr; 146(15):68. PubMed ID: 15373030
[No Abstract] [Full Text] [Related]
19. Acute hypersensitivity reaction to enfuvurtide upon re-challenge.
Beilke MA
Scand J Infect Dis; 2004; 36(10):778. PubMed ID: 15513412
[No Abstract] [Full Text] [Related]
20. [New drug class blocks virus-cell fusion. HIV not admitted].
MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584215
[No Abstract] [Full Text] [Related]
[Next] [New Search]
